Every Form 4 that Cardiff Oncology, Inc. (CRDF) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CRDF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRDF filings page.
Cardiff Oncology, Inc. director Gary W. Pace reported open-market purchases dated 2026-07-14 of 687,285 shares of common stock at $1.455 per share and 687,285 common stock purchase warrants with an exercise price of $1.33 per share. Following these transactions he holds 2,043,661 common shares directly plus 687,285 warrants. The warrants become exercisable on the later of six months after issuance or the “Authorized Share Increase Date” and remain exercisable for five and one-half years after that Initial Exercise Date.
Cardiff Oncology, Inc. director and Chief Executive Officer Mani Mohindru reported open-market purchases on July 14, 2026. She bought 34,364 shares of Common Stock at $1.455 per share and acquired 34,364 Common Stock Purchase Warrants exercisable at $1.33 per share. After these transactions, she holds 59,067 Common Shares directly and 34,364 warrants. The warrants become exercisable on the later of six months after issuance or the “Authorized Share Increase Date” and have a term of exercise of five and one-half years after the Initial Exercise Date.
Cardiff Oncology CEO Mani Mohindru reported an open-market purchase of 24,703 shares of Common Stock at $1.21 per share. This transaction took place on June 18, 2026 and represents a direct holding. Following the trade, her reported direct ownership totals 24,703 shares.
Cardiff Oncology director Gary W. Pace bought 30,000 shares of Common Stock in an open-market transaction. The shares were purchased at a price of $1.22 per share. Following this transaction, he directly owns 1,356,376 shares of Cardiff Oncology common stock.
Cardiff Oncology, Inc. director James O. Armitage was granted stock options covering 40,565 shares of common stock. The options have an exercise price of $1.59 per share and expire on June 11, 2036. After this award, he holds 228,104 derivative securities directly.
Cardiff Oncology director Lale White received a grant of stock options. The award covers 40,565 options to buy Cardiff Oncology common stock at an exercise price of $1.59 per share.
After this grant, White holds 199,246 derivative securities directly, with the options expiring on June 11, 2036.
Cardiff Oncology director Renee P. Tannenbaum received a new stock option grant covering 40,565 shares of common stock. These options have an exercise price of $1.59 per share and expire on June 11, 2036. Following this grant, she holds 209,331 derivative securities directly, reflecting routine equity-based compensation rather than an open-market purchase or sale.
Cardiff Oncology director Gary W. Pace received a new stock option grant. He was awarded options covering 40,565 shares of common stock at an exercise price of $1.59 per share. Following this grant, he holds options over a total of 228,104 shares.
Cardiff Oncology director receives stock option grant
Cardiff Oncology, Inc. director Rodney S. Markin was granted stock options covering 40,565 shares of common stock. These options have a conversion price of $1.59 per share and relate to an equal number of underlying common shares.
Following this award, Markin holds a total of 263,430 derivative securities, reflecting his updated stock option position with the company.
Cardiff Oncology Chief Operating Officer Ajay Aggarwal received a grant of stock options covering 400,000 shares of common stock. The options have an exercise price of $1.72 per share and expire on April 27, 2036, giving him a long-term incentive tied to the company’s share price.
According to the vesting schedule, 100,000 options vest on April 27, 2027, and 8,333 options vest monthly for 36 months beginning on May 27, 2027. After this grant, Aggarwal holds 400,000 stock options directly under this award.
Cardiff Oncology, Inc. reported that Chief Financial Officer Joshua B. Muntner received a grant of 486,650 stock options to purchase common stock at an exercise price of $1.58 per share. These options expire on April 6, 2036 and are held directly.
According to the vesting schedule, 121,663 options vest on April 6, 2027, and 10,139 options vest monthly for 36 months after that date. Following this award, Muntner holds a total of 487,150 stock options linked to Cardiff Oncology common stock.
Cardiff Oncology’s Chief Scientific Officer, Tod Smeal, received a grant of stock options covering 300,000 shares of common stock at an exercise price of $1.63 per share. These options were awarded as compensation, not purchased in the open market, and expire on April 14, 2036.
Following this grant, Smeal holds stock options for 1,279,805 shares in total. The award vests over time: 75,000 options vest on April 14, 2027, and 6,250 options vest monthly for 36 months thereafter, creating a multi‑year retention and incentive structure.
Cardiff Oncology, Inc. Chief Financial Officer Joshua B. Muntner reported a compensation-related grant of 486,650 stock options on April 6, 2026. These options allow him to purchase common stock at an exercise price of $1.58 per share and expire on April 6, 2036.
According to the vesting terms, 121,663 options vest on April 6, 2027, and 10,139 options vest monthly for 36 months thereafter. Following the grant, he holds 487,150 stock options and 500 shares of common stock, all reported as directly owned.
Cardiff Oncology, Inc. reported that Chief Executive Officer Mani Mohindru received a grant of stock options covering 600,000 shares of common stock. These options have an exercise price of $1.62 per share and expire on March 31, 2036.
The grant is compensation-related, not an open-market trade. Following this award, the filing shows option holdings of 968,766 stock options. A footnote states that 150,000 options vest on March 31, 2027, with 12,500 options vesting monthly for 36 months thereafter, creating a multi-year vesting schedule.
Cardiff Oncology, Inc. reported that Chief Accounting Officer Lindsay Brigitte Ute acquired a grant of 200,000 stock options on February 13, 2026. The options were granted at an exercise price of $0.00 per share, reflecting a cost-free award rather than an open-market purchase.
Following this transaction, Ute held a total of 1,025,334 stock options directly. According to the vesting terms, 50,000 options vest on February 13, 2027, and 4,166 options vest monthly for the subsequent 36 months, spreading the remainder of the award over three years.
Mohindru Mani reported acquisition or exercise transactions in this Form 4 filing.
Cardiff Oncology, Inc. reported that Interim CEO and director Mani Mohindru received a grant of stock options. The award covers 200,000 stock options, recorded at a price of $0.0000 per option, and increases her directly held option position to 368,766 options following the transaction.